Skip to content

Gross Profit at other companies

Amgen logo
AmgenAMGN
$5.87B+13.4%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$19.43M+154%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$34.32M+80.1%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$21.29M+0.6%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$14.74M+49.4%
Opko Health logo
Opko HealthOPK
$45.76M+7.4%

Other financials

Income statement

See full
Revenue$58.8M+10.3%
Operating income$11.9M-7.0%
Net income$8.7M-24.4%
EPS (diluted)$0.44-30.2%

Balance sheet

See full
Cash & equivalents$24.5M-46.6%
Total debt$68.4M+5,079%
Total equity$399.9M+2,054%
Total assets$504.6M+187%

Cash flow

See full
Operating cash flow$2.7M+405%
CapEx$73.0K
Free cash flow-$22.0M

Valuation

See full
Market cap$684.39M+102%
Enterprise value$728.29M+148%
P/E1.9×-7.2×
P/S2.3×+0.6×

Profitability

See full
Gross margin93.4%+3.7pp
Operating margin41.6%+19.9pp
Net margin121.5%+103pp
FCF margin-61.7%

Returns & leverage

See full
Return on equity174.1%
Debt / equity0.2×+0.1×
Current ratio2.6×+0.4×

Where this comes from

Calculated from Rigel Pharmaceuticals’s reported figures.

The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rigel Pharmaceuticals's gross profit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rigel Pharmaceuticals's gross profit?
Rigel Pharmaceuticals (RIGL) reported gross profit of $54.21M in Q1 2026.
How has Rigel Pharmaceuticals's gross profit changed year-over-year?
Rigel Pharmaceuticals's gross profit increased by 10.8% year-over-year, from $48.92M to $54.21M.
What is the long-term trend for Rigel Pharmaceuticals's gross profit?
Over 4 years (2021 to 2025), Rigel Pharmaceuticals's gross profit has grown at a 16.7% compound annual growth rate (CAGR), from $148.15M to $274.66M.
What does gross profit mean?
Revenue minus cost of revenue — the profit available to cover operating expenses, representing the company's pricing power and production efficiency.